top
Search terms
Results 1 - 10 of 38 - ordered by :
Pages: 1 2 3 4
Heart

Allison A Merz1, Susan Cheng1,2 1Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA 2Framingham Heart Study, Framingham, ...

Heart, Review, Allison A Merz, Susan Cheng

Date : 01/06/2016
Ehjournal

Introduction The results of the SIGNIFY (study assessing the morbiditymortality benefits of the If inhibitor ivabradine in patients with coronary artery disease) trial, which were recently published ...

European Heart Journal, CURRENT OPINION, Roberto Ferrari, Kim M. Fox

Date : 14/08/2015 Item size : 272782 bytes
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 21/09/2015
Ehjcardiovascrec

The results of the HOPE (Heart Outcomes Prevention Evaluation) trial caused much excitement when they were announced in 2000;3 HOPE was the first study to investigate the effects of ACE inhibition in ...

Cardiovascular Research, EDITORIALS: SPOTLIGHT ON LANDMARK PAPERS IN, Roberto Ferrari, Claudio Ceconi

Date : 01/11/2012
Ehjournal

Initially cloned from an activated macrophage cell line, GDF-15 has been proposed as a cell death promoter in several tumour cell lines, highlighting its potential role as an inductor of apoptosis in ...

European Heart Journal, Taddei, Stefano, Virdis, Agostino

Date : 01/05/2010
Ehjournal

Angiographic coronary artery disease was found in 2231 study participants. Introduction Sudden cardiac death (SCD) accounts for 50% of all fatal coronary heart disease events.1 Patients die ...

European Heart Journal, Pilz, Stefan, Scharnagl, Hubert, Tiran, Beate, Wellnitz, Britta, Seelhorst, Ursula, Boehm, Bernhard O., März, Winfried

Date : 01/11/2007
Ehjournal

The metabolic syndrome not only precedes cardiovascular conditions, and hence represents an important cluster of risk factors,1,2 but also remains relevant in patients with established coronary ...

European Heart Journal, Lüscher, Thomas F.

Date : 14/10/2015 Item size : 195267 bytes
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, Lüscher, Thomas F.

Date : 21/09/2015
Ehjournal

Adiponectin is an adipocytokine, which is mainly expressed in adipose tissue and has been identified as a potent insulin-sensitzing hormone.1 Adiponectin administration lowers glucose levels and ...

European Heart Journal, Kintscher, Ulrich

Date : 01/07/2007 Item size : 135455 bytes
Ehjournal

[...]ethnic differences in the prevalence of hypertension and its complications are evident, and may influence the approach to cardiovascular prevention.2,3 Furthermore, understanding of genetic, ...

European Heart Journal, Lip, Gregory Y.H., Butt, Mehmood

Date : 01/11/2008